0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > Alpha-fetoprotein

Alpha-fetoprotein

Brief Information

Name:Alpha-fetoprotein
Target Synonym:Alpha-Fetoglobulin,AFP,Alpha-fetoprotein,Alpha Fetoprotein,Alpha-1-Fetoprotein,HPAFP,AFPD,FETA,alpha-Fetoproteins
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:7
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

Par statut du produit :
Par catégorie de produit :
Par espèce :
Par étiquette :
Par conjugaison :
Cat . Non Espèces Description du produit Structure Pureté Caractéristique
ALN-H52H9 Human Human Alpha-fetoprotein, His Tag
ALN-H52H9-structure
ALN-H52H9-sds
ACRO Quality

Synonym Name

Alpha-fetoprotein

Background

Alpha-fetoprotein(AFP) is the first tumor marker with clinical application value found by human. AFP has an ability to induce the immune escapes through inhibiting the function of dendritic cells, natural killer cells, and T lymphocytes. By in vitro modification, the immunogenicity and immune response of AFP could be enhanced. AFP-modified immune cell vaccine or peptide vaccine has displayed the specific antitumor immunity against AFP-positive tumor cells and laid a better foundation for the immunotherapy of liver cancer. Alpha-fetoprotein is found in monomeric as well as dimeric and trimeric forms, and binds copper, nickel, fatty acids and bilirubin. The level of alpha-fetoprotein in amniotic fluid is used to measure renal loss of protein to screen for spina bifida and anencephaly.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
JWATM-203 JWATM-203; JWATM203 Phase 2 Clinical Suzhou Yaomingjunuo Biotechnology Co Ltd Carcinoma, Hepatocellular Details
SynOV1.1 Phase 2 Clinical Beijing Syngentech Co Ltd Solid tumours; Carcinoma, Hepatocellular Details
Alpha fetoprotein targeted T-cell therapy (Adaptimmune) AFP TCR (ADP-A2AFP); ADP-A2AFP; AFP TCR; AFPc332T Phase 1 Clinical Adaptimmune Llc Liver Neoplasms Details
ET1402L1-CART AFP/ET-1402; ET1402; ET-1402; AFP-CAR; ET-140202 Phase 1 Clinical Eureka Therapeutics Inc Liver Neoplasms; Carcinoma, Hepatocellular Details
TAEST-1901 TAEST-1901 Phase 1 Clinical Xiangxue Life Science Technology (Guangdong) Co Ltd Liver Neoplasms; Neoplasms Details
ET1402L1-ARTEMIS T cells Phase 1 Clinical Aeon Therapeutics (Beijing) Co Ltd Liver Neoplasms; Carcinoma, Hepatocellular Details
CPU-118 CPU-118 Phase 1 Clinical China Pharmaceutical University, Nanjing Qinling Pharmaceutical Technology Co Ltd Liver Neoplasms; Solid tumours; Neoplasms Details
JWATM-203 JWATM-203; JWATM203 Phase 2 Clinical Suzhou Yaomingjunuo Biotechnology Co Ltd Carcinoma, Hepatocellular Details
SynOV1.1 Phase 2 Clinical Beijing Syngentech Co Ltd Solid tumours; Carcinoma, Hepatocellular Details
Alpha fetoprotein targeted T-cell therapy (Adaptimmune) AFP TCR (ADP-A2AFP); ADP-A2AFP; AFP TCR; AFPc332T Phase 1 Clinical Adaptimmune Llc Liver Neoplasms Details
ET1402L1-CART AFP/ET-1402; ET1402; ET-1402; AFP-CAR; ET-140202 Phase 1 Clinical Eureka Therapeutics Inc Liver Neoplasms; Carcinoma, Hepatocellular Details
TAEST-1901 TAEST-1901 Phase 1 Clinical Xiangxue Life Science Technology (Guangdong) Co Ltd Liver Neoplasms; Neoplasms Details
ET1402L1-ARTEMIS T cells Phase 1 Clinical Aeon Therapeutics (Beijing) Co Ltd Liver Neoplasms; Carcinoma, Hepatocellular Details
CPU-118 CPU-118 Phase 1 Clinical China Pharmaceutical University, Nanjing Qinling Pharmaceutical Technology Co Ltd Liver Neoplasms; Solid tumours; Neoplasms Details

This web search service is supported by Google Inc.

totop

Laisser un message